Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zura BioZURA -1.07%22 3-1 Month Momentum % is 4.76% as of Aug. 15, 2026. GuruFocus rates ZURA with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 1,388 Biotechnology companies, Zura Bio ranks better than 75.07% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-15), Zura Bio's 3-1 Month Momentum % is 4.76%.
The industry rank for Zura Bio's 3-1 Month Momentum % or its related term are showing as below:
ZURA's 3-1 Month Momentum % is ranked better than 75.07% of 1388
companies
in the Biotechnology industry
Industry Median: -8.13
vs ZURA: 4.76
Zura Bio (NAS:ZURA) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Zura Bio 3-1 Month Momentum % Related Terms
ZURA vs ASMB, ARTV, EIKN: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Zura Bio's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zura Bio 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zura Bio's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Zura Bio's 3-1 Month Momentum % falls into.
Zura Bio (NAS:ZURA) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zura Bio (ZURA) has a 3-1 Month Momentum % of 4.76% as of Aug. 15, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Zura Bio and its competitors. According to the industry distribution chart, Zura Bio ranks #346 out of 1388 companies in the Biotechnology industry, placing it in the top 24.9%.
Is Zura Bio's 3-1 Month Momentum % too high?
Zura Bio's current 3-1 Month Momentum % is 4.76%. Based on the distribution chart, Zura Bio ranks #346 out of 1388 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zura Bio has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Zura Bio's 3-1 Month Momentum % compare to ASMB and ARTV?
According to the Biotechnology industry distribution chart, Zura Bio ranks #346 out of 1388 companies for 3-1 Month Momentum %. This places Zura Bio in the top 25% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Zura Bio and its competitors. Zura Bio's current 3-1 Month Momentum % is 4.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zura Bio stock overvalued right now?
Zura Bio (ZURA) has a current 3-1 Month Momentum % of 4.76%. The current 3-1 Month Momentum % is 4.76%. Zura Bio's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Zura Bio (ZURA), the current 3-1 Month Momentum % is 4.76% as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
22GF Score
Get the complete analysis for ZURA
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZURA has been successfully added to your 
